RxDoctor Payments Data

Benjamin Homra

Pain Medicine · la Place, LANPI 1437684891

Payments from drug & device makers

$1,286in general payments, 2019–2025

Across 43 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$342
  • Collegium Pharmaceutical, Inc.$239
  • Nalu Medical, Inc.$203
  • Forte Bio-pharma LLC$135
  • Abbott$98
  • SPR Therapeutics, Inc$63
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$1,286100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,286 in reported general payments places this provider in the 30th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$26,756
Medicare patients
55
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen759$104,426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen866$20,544
BelbucaBuprenorphine Hcl17$15,621
MovantikNaloxegol Oxalate36$14,642
Lidocaine70$6,882
Pregabalin256$5,087
Gabapentin441$4,002
Oxycodone Hcl129$2,667
Tizanidine Hcl231$2,226
Buprenorphine12$1,924
Morphine Sulfate ErMorphine Sulfate67$1,833
Cyclobenzaprine Hcl222$1,082
Methocarbamol105$1,010
Diclofenac Sodium18$860
Meloxicam319$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$239$15,62117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in la Place

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →